We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
More than 180 House lawmakers have sent a letter to the Biden administration pressuring the Department of Health and Human Services (HHS) to penalize companies that limit 340B drug discounts — the latest move in an ongoing tussle between drugmakers and the U.S. government. Read More
The proprietary therapy “has the potential to significantly advance the treatment of gliomas,” says Vijay Agarwal, the company’s founder and CEO, who is a practicing brain tumor surgeon. Read More
Novo Nordisk is going after Biocon Pharma, claiming patent infringement over a generic version of Novo’s weight loss drug Saxenda (liraglutide injection), a glucagon-like peptide-1 (GLP-1) receptor agonist. Read More
Proposed Senate legislation to cap the cost of insulin would cost the federal government in excess of $23 billion over the next 10 years — more than twice as much as the similar House version, according to a new analysis from the Congressional Budget Office (CBO). Read More
With the clock ticking loudly on must-pass user fee reauthorization, Senate Committee on Health, Education, Labor and Pensions (HELP) ranking member Richard Burr (R-N.C.) — a month after his committee advanced bipartisan user fee legislation to the Senate floor — has introduced an alternative user fee bill that strips out all riders and amendments on which the HELP committee had worked for months. Read More